Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Lucentis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.

NHS wins legal fight with pharma over off-label Avastin

NHS wins legal fight with pharma over off-label Avastin

and Novartis’Lucentis  to treat wet AMD, claiming that it broke EU and UK laws governing medicines licensing. ... The cost implications are clear, as the court judgement showed: it says Avastin’s list price is around £28 per injection; Eylea around

Bayer to challenge Avastin legal ruling

Bayer to challenge Avastin legal ruling age-related macular degeneration (wet AMD) in place of two licensed but much more expensive treatments, Bayer’s Eylea and Novartis’Lucentis. ... carried out to establish its equivalence in safety and efficacy with Lucentis in particular.

After Lucentis setback, Novartis trumpets data on follow-up drug

After Lucentis setback, Novartis trumpets data on follow-up drug After Lucentis setback, Novartis trumpets data on follow-up drug. Next gen eye treatment offers less frequent dosing. ... of Lucentis and Eylea for AMD, even though Avastin isn’t approved for the indication.

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III Allergan’ s abicipar matches AMD blockbuster Lucentis in phase III. Bayer's Eylea remains the drug to beat, however. ... Allergan and partner Molecular Partners say a pair of two studies of abicipar show that the drug is non-inferior to monthly dosing

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics